ROIV Latest Press Releases

-- November 10, 2026 --

Priovant Announces Publication of Phase 2 BEACON Results for Brepocitinib in Cutaneous Sarcoidosis in JAMA Dermatology Globe Newswire 1:24 PM

-- November 9, 2026 --

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended September 30, 2026 Globe Newswire 7:00 AM

Roivant Reports Financial Results for the Second Quarter Ended September 30, 2026, and Provides Business Update Globe Newswire 7:00 AM

-- October 29, 2026 --

Roivant Social Ventures Announced Support of No Patient Left Behind with Six-Figure Organizational Legacy Gift Globe Newswire 9:00 AM

-- October 21, 2026 --

Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU) Globe Newswire 7:00 AM

Roivant to Report Financial Results for the Second Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026 Globe Newswire 7:00 AM

Immunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026 Globe Newswire 7:00 AM

-- September 23, 2026 --

Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus Globe Newswire 7:00 AM

Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus Globe Newswire 7:00 AM

-- September 8, 2026 --

Pulmovant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study Globe Newswire 6:00 AM

Roivant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study Globe Newswire 6:00 AM

-- September 6, 2026 --

Pulmovant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026 Globe Newswire 1:00 AM

Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026, and Host Investor Call Globe Newswire 1:00 AM

-- August 27, 2026 --

Roivant Announces FDA Approval of LISRAYA (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S. Globe Newswire 3:29 PM

Priovant Announces FDA Approval of LISRAYA (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S. Globe Newswire 3:28 PM

-- August 26, 2026 --

JAMA Dermatology Publishes Skin-Specific Outcomes from Phase 3 VALOR Trial Of Brepocitinib in Dermatomyositis Globe Newswire 11:11 AM

-- August 6, 2026 --

Roivant Reports Financial Results for the First Quarter Ended June 30, 2026, and Provides Business Update Globe Newswire 7:00 AM

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026 Globe Newswire 7:00 AM

Priovant Announces First Patients Enrolled in Phase 3 Study (BEACON+) of Brepocitinib in Cutaneous Sarcoidosis (CS) Globe Newswire 7:00 AM

-- July 23, 2026 --

Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026 Globe Newswire 4:05 PM

Roivant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026 Globe Newswire 4:05 PM

Market Data Delayed 15 Minutes